George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
I agree. This is a really interesting element in the RNS.
T thought the whole RNS was very encouraging and great to see IMM updating shareholders again. Let's hope they give us regular updates in the future especially with so much going on. The RNS was also well written, clear and concise.
I was worried that the relationship with Avion and CNRS might have weakened; but they are both still here.
I wonder whether the new synthesis of the P140/Lupuzor platform with the greater IP protection the reason for the delay in the PK study.
Overall a very positive RNS. Well done to Tim and his team. There are real possibilities here......possibly groundbreaking in the autoimmune space. I'm feeling optimistic after this RNS..........aside from Tim's ever optimistic timelines. I like his optimism but I wish he was more cautious about timelines and not over-promise. These processes take time.
The train is finally leaving the station with Avion, CNRS and the new IMM team onboard. Great news.
Chiasma is due to approve the transaction on Tuesday. Once the new shares are issued, the divergent arbitrage will cease. That, together with the Amryt results next Friday will push the SP north....JMHO.
I think Amryt's figures next week will be good. The Aegerion fine has been paid off, so that's a few million to the bottom line and will sweeten the quarter-on-quarter comparisons....which the markets should like....as they focus on the future of the merged companies and not just the transaction.
I wonder will they make reference to Mycapssa's sales. Hopefully, they are growing strongly now and generating cash.
In the short term it's about generating cash, reducing debt and getting the merged balance sheet under control.......and then Oleogel. This company has a stellar future ahead of it IMHO.
I agree with you.....re the website.
The board changes look like they were well planned and in the works for a while. The website has been quickly updated. A refreshed board gives a strong positive signal as Avion and IMM prepare for the FDA green light and the start of the new Phase 3.
I wonder did Tim McC have a struggle with the old board. Who had oversight of the last Phase 3? Are these changes an attempt to distance IMM from the issues that arose with the design of that study? I see Avion's hand behind this.
I'm expecting IMM to rise steadily as this study gets underway. The potential is huge. A previous poster suggested that IMM could be taken over if the study shows positive results during its execution. I think that would be a real possibility.
I see
In order to get major shareholder approval, I suspect the relative valuations of the two companies were based on the share price of the recent fund-raisings.....$4 for Chiasma and $12.50 for Amryt. With Chiasma trading at $3 before the announcement, the share price went up. Amryt was trading around $13.5 and went down. The deal was probably done when Amryt did its December fund-raising. Just a guess.
WIth the significantly increased valuation post-merger, I wonder will Amryt move off the AIM market onto the main market. This would bring in institutional investors that don't normally buy on AIM with a possible re-rating of the price and better liquidity.
I really like the TPE Technology Platform. I wonder what is its potential in developing re-formulations of existing drugs.
I fell into this share by accident because of Fastnet, but have grown to like it. Hopefully good times ahead.
Thanks Diamondstar
When Amryt raised $40m last December, I thought they were in the market to buy another drug to add to their portfolio. This was one of their key objectives to better leverage their sales infrastructure. I had expected they might buy a cast-off drug from one of the big players with just a few years left in the patent life-cycle because of the limited cash they had raised.
I was really pleased to see that they used shares to buy a drug that has just been launched in the market and fits in to their own offering with real potential and synergies. Chiasma has a US sales team in place but with Amryt, MYCAPSSA can be launched through the Amryt worldwide network as well.
Chiasma raised $70m at $4 per share last July. They had $115m in cash at end March, most of which will be used to clear debt. Amryt has $118m.......so between them they are well positioned to see MYCAPSSA through a successful rollout.
Chiasma shares were $7 last June before the fund-raise and then fell to $3 earlier this year. After the announcement they recovered to $4. The drop in the Amryt price is probably due to traders taking advantage of the arbitrage opportunity.
The merger allows MYCAPSSA to be launched worldwide, leverages Amryt's existing sales network at minimal cost and provides funding for the further development of Chiasma's TPE technology platform and the IND.
I think its a fantastic deal for both companies and expect the share price of the combined company will start rising.
Hi Folks. Could someone point me in the direction of Alora Pharmaceutical financials. Can't find a website for them and finding it difficult to get detailed information on them other than the $75m Monroe credit facility they got 7 years ago. Thanks